Michel Gardet
Directeur/Membre du Conseil chez Phagenesis Ltd.
Profil
Michel Gardet is currently a Director at Phagenesis Ltd.
He was formerly a Director at Glycom A and Global Head-Business Operations at Nestle Health Science SA.
Postes actifs de Michel Gardet
| Sociétés | Poste | Début |
|---|---|---|
Phagenesis Ltd.
 Phagenesis Ltd. Pharmaceuticals: MajorHealth Technology Phagenesis Ltd. develops a treatment for dysphagia. Its product Phagenyx consists of a base station and a treatment catheter which in combination enable the healthcare professional to deliver personalized dysphagia treatment for every patient. The company was founded by Conor Joseph Mulrooney and Shaheen Hamdy in 2007 and is headquartered in Manchester, the United Kingdom. | Directeur/Membre du Conseil | - |
Anciens postes connus de Michel Gardet
| Sociétés | Poste | Fin |
|---|---|---|
Nestle Health Science SA
 Nestle Health Science SA Pharmaceuticals: OtherHealth Technology Nestle Health Science SA develops nutritional therapies. Its health management services include aging, brain health, chronic medical conditions, critical care and surgery, food allergy, gastro intestinal, metabolic diseases, and obesity pediatrics. The company was founded in 2011 and is headquartered in Vevey, Switzerland. | Directeur des opérations | - |
Glycom A/S
 Glycom A/S BiotechnologyHealth Technology Glycom A/S engages in the development, synthesis, and commercialization of human milk oligosaccharides. It develops chemical and enzymatic technologies for synthesis of human milk oligosaccharide powders. The company was founded by Gyuala Dekany, Mark von Itzstein, Joachim Erich Thiem, Arnold Stutz, and Inge Lundt on March 22, 2005 and is headquartered in Horsholm, Denmark. | Directeur/Membre du Conseil | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
Glycom A/S
Glycom A/S BiotechnologyHealth Technology Glycom A/S engages in the development, synthesis, and commercialization of human milk oligosaccharides. It develops chemical and enzymatic technologies for synthesis of human milk oligosaccharide powders. The company was founded by Gyuala Dekany, Mark von Itzstein, Joachim Erich Thiem, Arnold Stutz, and Inge Lundt on March 22, 2005 and is headquartered in Horsholm, Denmark. | Health Technology |
Nestle Health Science SA
Nestle Health Science SA Pharmaceuticals: OtherHealth Technology Nestle Health Science SA develops nutritional therapies. Its health management services include aging, brain health, chronic medical conditions, critical care and surgery, food allergy, gastro intestinal, metabolic diseases, and obesity pediatrics. The company was founded in 2011 and is headquartered in Vevey, Switzerland. | Health Technology |
Phagenesis Ltd.
Phagenesis Ltd. Pharmaceuticals: MajorHealth Technology Phagenesis Ltd. develops a treatment for dysphagia. Its product Phagenyx consists of a base station and a treatment catheter which in combination enable the healthcare professional to deliver personalized dysphagia treatment for every patient. The company was founded by Conor Joseph Mulrooney and Shaheen Hamdy in 2007 and is headquartered in Manchester, the United Kingdom. | Health Technology |
